Although anti-angiogenic agents combined with EGFR-TKIs demonstrated beneficial effects for PFS in our meta-analysis, anti-angiogenic agents may also cause adverse reactions, such as epistaxis, hypertension, proteinuria, bleeding, and tracheoesophageal fistula [41]. This evidence concerns the gene EGFR and epistaxis.